Atea Pharmaceuticals
(NASDAQ) AVIR
Atea Pharmaceuticals Financials at a Glance
Market Cap
$399.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$169.52M
EPS (TTM)
-$2.12
P/E Ratio
-2.35
Dividend
$0.00
Beta (Volatility)
0.91 (Low)
Dividend
$0.00
Beta (Volatility)
0.91 (Low)
Price
$4.96
Volume
306,553
Open
$4.96
Price
$4.96
Volume
306,553
Open
$4.96
Previous Close
$4.99
Daily Range
$4.75 - $5.00
52-Week Range
$2.78 - $6.45
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.91 (Low)
Price
$4.96
Volume
306,553
Open
$4.96
Previous Close
$4.99
Daily Range
$4.75 - $5.00
52-Week Range
$2.78 - $6.45
Estimated Earnings Date
Aug 6, 2026
AVIR News
AVIR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Atea Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
55
CEO
Jean-Pierre Sommadossi, PhD
Website
www.ateapharma.comHeadquarters
Boston, MA 02110, US
AVIR Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-57.01%
Return on Capital
-65.47%
Return on Assets
-63.47%
Earnings Yield
-42.55%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$399.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
80.03M
Volume
306.55K
Avg. Volume
331.99K
Financials (TTM)
Gross Profit
-$40.76M
Operating Income
-$189.85M
EBITDA
-$179.89M
Operating Cash Flow
-$147.86M
Capital Expenditure
$0.00
Free Cash Flow
-$147.86M
Cash & ST Invst.
$256.01M
Total Debt
$634.00K
Atea Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$104.00K
+97.0%
Gross Margin
0.00%
N/A
Market Cap
$399.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$7.26M
N/A
Employees
55
N/A
Net Income
-$45.44M
-32.6%
EBITDA
-$45.29M
-33.3%
Quarterly Fundamentals
Total Cash
$256.01M
-39.8%
Total Debt
$634.00K
-56.1%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$634.00K
-21.8%
Return on Assets
-63.47%
N/A
Return on Invested Capital
-81.24%
N/A
Free Cash Flow
-$46.39M
-51.8%
Operating Cash Flow
-$46.39M
-51.8%